A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

B. H. O'Neil, A. J. Scott, W. W. Ma, S. J. Cohen, D. L. Aisner, A. R. Menter, M. A. Tejani, J. K. Cho, J. Granfortuna, L. Coveler, O. O. Olowokure, J. C. Baranda, M. Cusnir, P. Phillip, J. Boles, R. Nazemzadeh, M. Rarick, D. J. Cohen, J. Radford, L. FehrenbacherR. Bajaj, V. Bathini, P. Fanta, J. Berlin, A. J. McRee, R. Maguire, F. Wilhelm, M. Maniar, A. Jimeno, C. L. Gomes, Wells A. Messersmith

Research output: Contribution to journalArticle

29 Scopus citations

Fingerprint Dive into the research topics of 'A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences